[go: up one dir, main page]

NO20092280L - Aptamer mot midkin og anvendelser derav - Google Patents

Aptamer mot midkin og anvendelser derav

Info

Publication number
NO20092280L
NO20092280L NO20092280A NO20092280A NO20092280L NO 20092280 L NO20092280 L NO 20092280L NO 20092280 A NO20092280 A NO 20092280A NO 20092280 A NO20092280 A NO 20092280A NO 20092280 L NO20092280 L NO 20092280L
Authority
NO
Norway
Prior art keywords
aptamer
inhibitory activity
against midkine
activity against
midkin
Prior art date
Application number
NO20092280A
Other languages
English (en)
Other versions
NO342010B1 (no
Inventor
Shin Miyakawa
Masatoshi Fujiwara
Yoshikazu Nakamura
Takashi Matsui
Hajime Takashima
Original Assignee
Ribomic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribomic Inc filed Critical Ribomic Inc
Publication of NO20092280L publication Critical patent/NO20092280L/no
Publication of NO342010B1 publication Critical patent/NO342010B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Det beskrives en høykvalitets aptamer mot midkine. Det beskrives en aptamer med en inhibitorisk aktivitet mot midkine; et kompleks omfattende en aptamer med en bindingsaktivitet eller inhibitorisk aktivitet mot midkine og en funksjonell substans (for eksempel affinitetssubstans, substanser for merking, enzymer, medikamentavleveringsvehikler, medikamenter og liknende); et farmasøytisk medikament, cellemigreringsinhibitor, diagnostisk middel, merkingsmiddel og liknende omfattende en aptamer med en bindingsaktivitet eller inhibitorisk aktivitet mot midkine, eller et kompleks omfattende aptameren og en funksjonell substans; en cellemigreringsinhibitor, en diagnostisk reagens, et merkingsmiddel og liknende.
NO20092280A 2006-11-14 2009-06-12 Aptamer mot midkine og anvendelse derav NO342010B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006308482 2006-11-14
PCT/JP2007/072099 WO2008059877A1 (en) 2006-11-14 2007-11-14 Aptamer against midkine and use thereof

Publications (2)

Publication Number Publication Date
NO20092280L true NO20092280L (no) 2009-08-14
NO342010B1 NO342010B1 (no) 2018-03-12

Family

ID=39401681

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092280A NO342010B1 (no) 2006-11-14 2009-06-12 Aptamer mot midkine og anvendelse derav

Country Status (26)

Country Link
US (1) US8080649B2 (no)
EP (1) EP2096167B1 (no)
JP (1) JP5190573B2 (no)
KR (1) KR101516024B1 (no)
CN (1) CN101573446B (no)
AU (1) AU2007320401B2 (no)
BR (1) BRPI0718913A2 (no)
CA (1) CA2669523C (no)
CO (1) CO6190535A2 (no)
CY (1) CY1113679T1 (no)
DK (1) DK2096167T3 (no)
ES (1) ES2397715T3 (no)
HR (1) HRP20130012T1 (no)
IL (1) IL198705A (no)
MX (1) MX2009005148A (no)
MY (1) MY147374A (no)
NO (1) NO342010B1 (no)
NZ (1) NZ577396A (no)
PL (1) PL2096167T3 (no)
PT (1) PT2096167E (no)
RU (1) RU2460794C2 (no)
SI (1) SI2096167T1 (no)
TW (1) TWI481713B (no)
UA (1) UA100847C2 (no)
WO (1) WO2008059877A1 (no)
ZA (1) ZA200903562B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128934B2 (en) 2005-11-14 2012-03-06 Ribomic, Inc. Method for treatment or prevention of disease associated with functional disorder of regulatory T cell
ES2543222T3 (es) 2008-09-24 2015-08-17 Ribomic Inc. Aptámero para NGF y uso del mismo
JP6041373B2 (ja) * 2010-02-01 2016-12-07 Ｎｅｃソリューションイノベータ株式会社 ＴＮＦ−αに結合するアプタマー分子
BR112012024232A8 (pt) * 2010-03-24 2018-02-06 Fujimoto Seiyaku Kk "aptâmero de 73 nucleotídeos ou menos, complexo, composição farmacêutica e medicamento anti-dor"
PH12013501078A1 (en) 2010-12-20 2018-03-21 Colgate Palmolive Co Gelatin encapsulated oral care composition containing hydrophilic active hydrophobic structuring agent and oil carrier
RU2633510C2 (ru) * 2011-09-28 2017-10-12 Рибомик Инк. Аптамер против ngf и его применение
JP6020888B2 (ja) * 2012-06-29 2016-11-02 国立大学法人名古屋大学 エポキシエイコサトリエン酸関連疾患の予防又は治療
US9506070B2 (en) 2012-11-21 2016-11-29 Ribomic Inc. Aptamer against midkine and applications thereof
RU2549704C1 (ru) * 2014-03-26 2015-04-27 Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) Рнк-аптамер, обладающий способностью узнавать характерные для рассеянного склероза аутоантитела
ES3013534T3 (en) 2016-07-01 2025-04-14 Somalogic Operating Co Inc Oligonucleotides comprising modified nucleosides
KR101985300B1 (ko) * 2016-07-19 2019-06-03 삼성전자주식회사 미드카인 저해제를 포함하는 뇌종양 치료 또는 예방용 약학 조성물
KR102841342B1 (ko) * 2018-06-29 2025-07-31 가부시키가이샤 리보믹 압타머 제제
CN109536505B (zh) * 2018-12-07 2021-11-09 暨南大学 鬼臼毒素的核酸适配体及其应用
WO2020124095A1 (en) * 2018-12-14 2020-06-18 Board Of Regents, The University Of Texas System Aka Dna aptamers and use thereof for the treatment of cancer
WO2020241493A1 (ja) * 2019-05-24 2020-12-03 株式会社リボミック 骨形成や骨代謝の異常に関連する疾患の治療薬

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
JP3842304B2 (ja) 1992-10-08 2006-11-08 喬 村松 癌の診断、治療薬
WO1999003493A1 (en) 1997-07-14 1999-01-28 Meiji Milk Products Co., Ltd. Drugs containing as the active ingredient midkine or inhibitors thereof
AU762437B2 (en) 1998-08-24 2003-06-26 Medical Therapies Limited Pharmaceutical compositions for the prevention and treatment of atherosclerosis and restenosis after PTCA
US6858390B2 (en) * 1998-12-31 2005-02-22 Ingeneus Corporation Aptamers containing sequences of nucleic acid or nucleic acid analogues bound homologously, or in novel complexes
JP2000354487A (ja) * 1999-06-15 2000-12-26 Takashi Muramatsu ミッドカイン受容体
WO2004078210A1 (ja) 2003-03-06 2004-09-16 Takashi Muramatsu 開腹手術後の癒着の予防剤
JP4646070B2 (ja) 2003-03-27 2011-03-09 メディカル セラピーズ リミテッド 関節炎関連遺伝子及びこれの関節炎検査等への利用
JP3940097B2 (ja) 2003-05-20 2007-07-04 株式会社リボミック 翻訳開始因子ｅＩＦ４Ｅに結合するリガンド
JP2007297282A (ja) 2004-08-13 2007-11-15 Cell Signals Inc 子宮内膜症の発生の際にミッドカインによって起こる影響
JP2006141305A (ja) 2004-11-22 2006-06-08 Univ Of Tokyo 翻訳開始因子ｅＩＦ４Ｇに結合するリボ核酸
JP2006211905A (ja) 2005-02-01 2006-08-17 Univ Of Tokyo 腫瘍壊死因子受容体ファミリータンパク質に結合する核酸リガンド
JP2006308482A (ja) 2005-04-28 2006-11-09 Sanyo Electric Co Ltd 検出装置

Also Published As

Publication number Publication date
SI2096167T1 (sl) 2013-02-28
IL198705A0 (en) 2011-08-01
BRPI0718913A2 (pt) 2013-12-10
US20100004432A1 (en) 2010-01-07
WO2008059877A1 (en) 2008-05-22
TW200831668A (en) 2008-08-01
EP2096167B1 (en) 2012-10-17
CN101573446A (zh) 2009-11-04
CO6190535A2 (es) 2010-08-19
CY1113679T1 (el) 2016-06-22
NZ577396A (en) 2011-12-22
JPWO2008059877A1 (ja) 2010-03-04
EP2096167A1 (en) 2009-09-02
KR101516024B1 (ko) 2015-04-29
TWI481713B (zh) 2015-04-21
IL198705A (en) 2014-11-30
AU2007320401B2 (en) 2012-12-06
HK1135729A1 (en) 2010-06-11
PT2096167E (pt) 2013-01-25
CA2669523C (en) 2016-06-21
UA100847C2 (uk) 2013-02-11
CA2669523A1 (en) 2008-05-22
KR20090097879A (ko) 2009-09-16
US8080649B2 (en) 2011-12-20
NO342010B1 (no) 2018-03-12
RU2460794C2 (ru) 2012-09-10
ES2397715T3 (es) 2013-03-08
RU2009122476A (ru) 2010-12-20
DK2096167T3 (da) 2013-02-04
MY147374A (en) 2012-11-30
MX2009005148A (es) 2009-08-24
JP5190573B2 (ja) 2013-04-24
ZA200903562B (en) 2010-07-28
HRP20130012T1 (hr) 2013-01-31
EP2096167A4 (en) 2009-11-11
AU2007320401A1 (en) 2008-05-22
PL2096167T3 (pl) 2013-03-29
CN101573446B (zh) 2013-07-17

Similar Documents

Publication Publication Date Title
NO20092280L (no) Aptamer mot midkin og anvendelser derav
WO2008036658A3 (en) Method and system for controlled infusion of therapeutic substances
WO2007137187A3 (en) System and method for determining individualized medical intervention for a disease state
PL2330527T3 (pl) Układ i sposób określania informacji dotyczących podawania leków
WO2008103620A3 (en) Modular combination of medication infusion and analyte monitoring
EP2099364B8 (en) Detection of the detachment of immobilized contrast agent in medical imaging applications
WO2008039769A3 (en) Methods and devices for analyzing small rna molecules
WO2008109878A3 (en) Testing device
EP2069522A4 (en) LIQUID-CONTAINING ENZYME AND ADMINISTRATION SYSTEM FOR DETECTING ANALYTES ON SURFACES
HUE061300T2 (hu) Gyógyszer szállítórendszerek hidrofób gyógyszerekhez és az azokat tartalmazó készítmények
EP2186889A4 (en) CDCA1-PEPTIDE AND THIS INCLUDING PHARMACEUTICALS
BRPI0716196A2 (pt) Sistemas de distribuição de fármacos que compreendem soluções sólidas de fármacos fracamente básicos.
EP2036574A4 (en) MEDICAL AGENT FOR THE TREATMENT OF FAT, DIABETES AND DISEASES IN CONNECTION WITH IMPROVED GLUCOSE TOLERANCE
MX2008007716A (es) Metodo para eliminar extra corporalmente de la sangre un microbio patogeno, una celula inflamatoria o una proteina inflamatoria.
WO2006095259A3 (en) Biomarkers for cardiovascular side-effects induced by cox-2 inhibitory compounds
EP2071025A4 (en) PRIMER SET FOR THE REINFORCEMENT OF THE UGT1A1 GENE, REAGENT FOR THE REINFORCEMENT OF THE UGT1A1 GENE THEREFOR AND APPLICATION THEREOF
WO2008081094A3 (fr) Methode de mesure fonctionnelle de l'activite de la thrombomoduline plasmatique
WO2006086442A3 (en) Method of detecting abnormal tissue
AR077049A1 (es) Aptamero contra quimasa y su uso
BRPI0919268A8 (pt) Aptâmero que se liga ao ngf e medicamento
DK1842113T3 (da) Holdbarhedsindikatoretiket efter åbning til levnedsmidler og lignende
WO2006114805A3 (en) Use of hmgb2 and hmgb3 proteins for medical applications
WO2006060393A3 (en) Biological systems analysis
WO2009063998A1 (ja) 疎水性物質付加核酸及びその使用
WO2007132379A3 (en) A device for drug administration and/or monitoring the status of a patient

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees